AAAAAA
Results: 1-25/28
Authors:
SPINLER SA
NAWARSKAS JJ
Citation: Sa. Spinler et Jj. Nawarskas, LOW-MOLECULAR-WEIGHT HEPARINS FOR ACUTE CORONARY SYNDROMES, The Annals of pharmacotherapy, 32(1), 1998, pp. 103-110
Authors:
SPINLER SA
NAWARSKAS JJ
FOOTE EF
SABAPATHI D
CONNORS JE
MARCHLINSKI FE
Citation: Sa. Spinler et al., CLINICAL PRESENTATION AND ANALYSIS OF RISK-FACTORS FOR INFECTIOUS COMPLICATIONS OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATIONS AT A UNIVERSITY MEDICAL-CENTER, Clinical infectious diseases, 26(5), 1998, pp. 1111-1116
Authors:
NAWARSKAS JJ
SPINLER SA
Citation: Jj. Nawarskas et Sa. Spinler, DOES ASPIRIN INTERFERE WITH THE THERAPEUTIC EFFICACY OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS IN HYPERTENSION OR CONGESTIVE-HEART-FAILURE, Pharmacotherapy, 18(5), 1998, pp. 1041-1052
Authors:
MEISTER FL
STRINGER KA
SPINLER SA
GONZALEZ E
TALBERT RL
WEINER B
GUERRERO RM
SMITH R
Citation: Fl. Meister et al., THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION, Pharmacotherapy, 18(4), 1998, pp. 686-698
Authors:
EARL GL
STANEK EJ
SPINLER SA
Citation: Gl. Earl et al., INTRAVENOUS NITROGLYCERIN TOLERANCE IN PATIENTS WITH ISCHEMIC CARDIOMYOPATHY AND CONGESTIVE-HEART-FAILURE, Pharmacotherapy, 18(1), 1998, pp. 203-209
Authors:
SPINLER SA
Citation: Sa. Spinler, UNFRACTIONATED HEPARIN DOSING IN THE FRIC STUDY, Circulation, 97(14), 1998, pp. 1424-1424
Authors:
SPINLER SA
Citation: Sa. Spinler, CARDIOVASCULAR DRUG PRESCRIBING PATTERNS - WHERE IS THE EVIDENCE OF IMPROVEMENT, American journal of managed care, 3(11), 1997, pp. 1779-1780
Authors:
NAWARSKAS JJ
MCCARTHY DM
SPINLER SA
Citation: Jj. Nawarskas et al., DIGOXIN TOXICITY SECONDARY TO CLARITHROMYCIN THERAPY, The Annals of pharmacotherapy, 31(7-8), 1997, pp. 864-866
Authors:
SPINLER SA
MIKHAIL PA
Citation: Sa. Spinler et Pa. Mikhail, PREHOSPITAL-INITIATED THROMBOLYSIS, The Annals of pharmacotherapy, 31(11), 1997, pp. 1339-1346
Authors:
CHENG JWM
CHARLAND SL
SHAW LM
KOBRIN S
GOLDFARB S
STANEK EJ
SPINLER SA
Citation: Jwm. Cheng et al., IS THE VOLUME OF DISTRIBUTION OF DIGOXIN REDUCED IN PATIENTS WITH RENAL DYSFUNCTION - DETERMINING DIGOXIN PHARMACOKINETICS BY FLUORESCENCE POLARIZATION IMMUNOASSAY, Pharmacotherapy, 17(3), 1997, pp. 584-590
Authors:
STANEK EJ
CHENG JWM
PEEPLES PJ
SIMKO RJ
SPINLER SA
Citation: Ej. Stanek et al., PATIENT PREFERENCES FOR THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL-INFARCTION, Medical decision making, 17(4), 1997, pp. 464-471
Authors:
SPINLER SA
BOSSO J
HAK L
HAMMOND R
KRADJAN W
POIRIER T
WAGNER M
Citation: Sa. Spinler et al., REPORT OF THE TASK-FORCE CONCERNING BOARD CERTIFICATION REQUIREMENTS FOR PHARMACY PRACTICE FACULTY, American journal of pharmaceutical education, 61(2), 1997, pp. 213-216
Authors:
NAWARSKAS JJ
SPINLER SA
Citation: Jj. Nawarskas et Sa. Spinler, ADDITIONAL ANTICOAGULANT STRATEGIES FOR MANAGING HEPARIN-INDUCED THROMBOCYTOPENIA, American journal of health-system pharmacy, 53(8), 1996, pp. 945-945
Authors:
HSU I
SPINLER SA
Citation: I. Hsu et Sa. Spinler, MORE ON COMPARISON OF HMG-COA REDUCTASE INHIBITORS, The Annals of pharmacotherapy, 30(4), 1996, pp. 414-415
Authors:
SPINLER SA
NAWARSKAS JJ
Citation: Sa. Spinler et Jj. Nawarskas, ARE THE DRUG NAMES COUMADIN AND WARFARIN INTERCHANGEABLE, Journal of the American College of Cardiology, 27(6), 1996, pp. 1552-1553
Authors:
HSU I
SPINLER SA
JOHNSON NE
Citation: I. Hsu et al., COMPARATIVE-EVALUATION OF THE SAFETY AND EFFICACY OF HMG-COA REDUCTASE INHIBITOR MONOTHERAPY IN THE TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, The Annals of pharmacotherapy, 29(7-8), 1995, pp. 743-759
Authors:
CHENG JWM
CHARLAND SL
GOLDFARB S
SPINLER SA
Citation: Jwm. Cheng et al., EFFECTS OF RENAL-FUNCTION ON RECAINAM PHARMACOKINETICS AND PHARMACODYNAMICS, Clinical pharmacology and therapeutics, 57(5), 1995, pp. 492-498
Authors:
SPINLER SA
CHENG JWM
KINDWALL KE
CHARLAND SL
Citation: Sa. Spinler et al., POSSIBLE INHIBITION OF HEPATIC-METABOLISM OF QUINIDINE BY ERYTHROMYCIN, Clinical pharmacology and therapeutics, 57(1), 1995, pp. 89-94
Authors:
PLASTINO KA
CONNORS JE
SPINLER SA
Citation: Ka. Plastino et al., POSSIBLE SYNERGY BETWEEN AMINOGLYCOSIDES AND VANCOMYCIN IN THE TREATMENT OF STAPHYLOCOCCUS- EPIDERMIDIS ENDOCARDITIS, The Annals of pharmacotherapy, 28(6), 1994, pp. 737-739
Authors:
CHENG JWM
SPINLER SA
Citation: Jwm. Cheng et Sa. Spinler, SHOULD ALL PATIENTS WITH DILATED CARDIOMYOPATHY RECEIVE CHRONIC ANTICOAGULATION, The Annals of pharmacotherapy, 28(5), 1994, pp. 604-609
Authors:
SPINLER SA
CZIRAKY MJ
Citation: Sa. Spinler et Mj. Cziraky, LIPOPROTEIN(A) - PHYSIOLOGICAL-FUNCTION, ASSOCIATION WITH ATHEROSCLEROSIS, AND EFFECTS OF LIPID-LOWERING DRUG-THERAPY, The Annals of pharmacotherapy, 28(3), 1994, pp. 343-351
Authors:
WITTBRODT ET
SPINLER SA
Citation: Et. Wittbrodt et Sa. Spinler, PREVENTION OF ANAPHYLACTOID REACTIONS IN HIGH-RISK PATIENTS RECEIVINGRADIOGRAPHIC CONTRAST-MEDIA, The Annals of pharmacotherapy, 28(2), 1994, pp. 236-241
Authors:
STANEK EJ
TUCKER PP
CHENG JWM
SPINLER SA
Citation: Ej. Stanek et al., PATIENT PREFERENCES OF TPA AND STREPTOKINASE, Circulation, 90(4), 1994, pp. 527-527
Authors:
STANEK EJ
TUCKER PP
CHENG JWM
SPINLER SA
Citation: Ej. Stanek et al., PATIENT PREFERENCES OF TPA AND STREPTOKINASE, Circulation, 90(4), 1994, pp. 527-527
Authors:
MORALES E
SPINLER SA
CHIN MM
JOZEFIAK E
Citation: E. Morales et al., CRITERIA FOR USE OF HYPOLIPIDEMIC AGENTS IN ADULTS, American journal of hospital pharmacy, 51(22), 1994, pp. 2837-2841